Shares of Verici Dx plc (LON:VRCI – Get Free Report) hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as GBX 2.50 ($0.03) and last traded at GBX 2.69 ($0.03), with a volume of 145282 shares trading hands. The stock had previously closed at GBX 2.63 ($0.03).
Verici Dx Trading Up 2.3 %
The company has a current ratio of 4.54, a quick ratio of 8.49 and a debt-to-equity ratio of 4.65. The company has a fifty day moving average price of GBX 4.16 and a 200-day moving average price of GBX 6.01. The firm has a market cap of £6.51 million, a price-to-earnings ratio of -134.40 and a beta of 1.59.
Verici Dx Company Profile
Verici Dx plc develops prognostic and diagnostic tests for kidney transplant patients. Its lead products are Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection.
Further Reading
- Five stocks we like better than Verici Dx
- 3 Stocks to Consider Buying in October
- NVIDIA’s Blackwell Chips Set for Arizona Manufacturing by TSMC
- Buy P&G Now, Before It Sets A New All-Time High
- Okta: Bullish Signals Suggest a Market Reversal Is Underway
- What is the Dow Jones Industrial Average (DJIA)?
- BlackRock Makes Waves With $12B Private Credit Acquisition
Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.
